{
    "nctId": "NCT01984138",
    "briefTitle": "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy",
    "officialTitle": "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy",
    "overallStatus": "RECRUITING",
    "conditions": "Estrogen Receptor Positive Breast Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "What is the number of participants that show improvement of symptoms using vaginal estrogen as compared to the control.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. be female\n2. be 18 years of age or older.\n3. have stage I-III ER+ breast cancer\n4. be post-menopausal as defined by any of the following: age \\>55 years, history of bilateral oophorectomy, amenorrhea for 1 year with intact uterus and ovaries, or serum estradiol and FSH concentrations in the post-menopausal range along with either amenorrhea for 6 months or previous hysterectomy.\n5. currently take adjuvant AI therapy\n6. have vaginal dryness, dyspareunia, or \u22653 urinary tract infections per year since starting AI therapy\n7. Patients must agree not to use any additional estrogen during the five year study period. However, use of non-estrogen containing lubricants prior to sexual intercourse, or otherwise, is allowed.\n\nExclusion Criteria:\n\n1. use of any exogenous estrogen within the preceding four weeks\n2. current vaginal infection.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}